Empagliflozin in T1D

This study is for:

  • People with T1D diagnosed in the past 100 days

  • Aged between 18 and 40 years

About this study

This study will determine if a drug commonly used to treat T2D is also safe and effective in the early stages of type 1 diabetes and whether it helps preserve pancreas function. It is suitable for people aged between 18 and 40 who have been diagnosed with T1D within 3 months of joining the study.